Abstract:Abstract Background The gut microbiota (GM) and their metabolites have garnered significant attention for their roles in metabolic syndrome (MetS) and associated conditions. MetS, characterized by a cluster of metabolic abnormalities, significantly increases the risk of cardiovascular disease (CVD), obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). The dysbiosis of gut microbiota, marked by changes in microbial composition and function, has been implicated in the pathogenesis of MetS. Main body This review synthesizes recent findings elucidating the influence of GM composition and microbiota-derived metabolites on MetS pathogenesis and progression. Notably, alterations in GM composition and dysregulation of metabolites such as short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), polyamines, amino acids, and indole derivatives have been implicated in MetS development. These metabolites play crucial roles in metabolic processes, and their imbalance can trigger or exacerbate metabolic disturbances associated with MetS. Various therapeutic approaches, including dietary interventions, probiotics, prebiotics, and precision medicine targeting specific metabolites, offer promising strategies for managing MetS. These interventions aim to restore a healthy GM balance and regulate the production of beneficial metabolites. Conclusion The complexity of GM interactions and their systemic effects necessitate more standardized research methodologies. Future investigations focusing on personalized therapeutic interventions and non-invasive diagnostic tools are warranted to address the complexities of MetS management. Advancing our understanding of the GM-metabolite-MetS axis will be crucial for developing effective, targeted treatments and improving patient outcomes in MetS.

Gut Microbiota Disorders and Metabolic Syndrome: Tales of a Crosstalk Process

Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions

Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome

Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies

Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites

Exploring the Gut Microbiota: Key Insights into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes

Gut Microbiota, Immunity, and Bile Acid Metabolism: Decoding Metabolic Disease Interactions

Role of the intestine and its gut microbiota in metabolic syndrome and obesity

Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders

Harnessing the Power of the Gut Microbiome: A Review of Supplementation Therapies for Metabolic Syndrome

You Are What You Eat-The Relationship between Diet, Microbiota, and Metabolic Disorders-A Review

A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome

Crosstalk between intestinal flora and human iron metabolism: the role in metabolic syndrome-related comorbidities and its potential clinical application

Food Additives' Impact on Gut Microbiota and Metabolic Syndrome: A Systematic Review

The Role of Gut Microbiota Associated Metabolites in Digestive Disorders

Gut Microbiota-Derived Metabolites in the Development of Diseases

Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?

Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia.

Long-term changes in the C-fiber-induced excitation in the spinal dorsal horn revealed by optical imaging

Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders

Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics